Eli Lilly Sees $2M Bearish Put Contract as Stock Trades Near 52-Week Lows

By TrendSpider Editor

A single unusual put contract on Eli Lilly and Company (LLY) worth $2,060,743 in premium has surfaced, flagging notable bearish positioning against the pharmaceutical giant. The contract targets a $1,240 strike, sitting meaningfully out of the money relative to LLY's current price of $1,364.35, whic

Eli Lilly Sees $2M Bearish Put Contract as Stock Trades Near 52-Week Lows

A single unusual put contract on Eli Lilly and Company (LLY) worth $2,060,743 in premium has surfaced, flagging notable bearish positioning against the pharmaceutical giant. The contract targets a $1,240 strike, sitting meaningfully out of the money relative to LLY's current price of $1,364.35, which itself sits closer to the bottom of its 52-week range of $850.51 to $1,453. With the stock down just 0.22% on the session, the options flow is the standout story today, suggesting at least one large player is bracing for further downside heading into the new year.

Key Drivers of the LLY Stock Move

Looking ahead, the forward setup for LLY is complicated by its position in the weight-loss drug race, where competitive pressures from rivals continue to generate headlines and investor uncertainty. The stock is currently trading closer to the lower half of its 52-week range, and any macro or clinical catalysts between now and mid-January could be the deciding factor for whether this put pays off. Investors should watch for pipeline updates, pricing news related to GLP-1 therapies, and any broader healthcare policy developments that could act as near-term triggers in either direction.

LLY Unusual Options Activity

One unusual contract was flagged in today's session for Eli Lilly:

The 302% open interest ratio is a key detail here. When a contract's volume exceeds its open interest by this margin, it typically indicates new money entering a position rather than a rollover or existing hedge. With zero call contracts flagged in today's unusual flow, the options market activity is entirely skewed to the downside for LLY on this session.

LLY Seasonality

Historically, large-cap pharmaceutical stocks like LLY tend to see elevated options activity in the November to January window as institutional players position ahead of year-end portfolio rebalancing and early-year earnings catalysts. A January 15, 2027 expiration places this contract squarely within that seasonally active window, adding context to the timing of this unusually large put bet.

LLY Relative Performance

LLY's current price of $1,364.35 represents a meaningful retreat from its 52-week high of $1,453, with today's marginal decline of 0.22% keeping the stock in a broader consolidation pattern. At roughly 94% of its 52-week peak, Lilly has held up better than some large-cap biotech peers that have seen steeper drawdowns this year, though the gap between current price and the 52-week low of $850.51 underscores just how wide the trading range has been over the past year.

More on LLY

Latest Market News